Clinical Trials for Mesothelioma Patients: AZD2171 Prior Concurrent Therapy

Read the concurrent therapy criteria for a current clinical trial being conducted to study the effects of AZD2171 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Prior Concurrent Therapy:
• No more than 1 prior cytotoxic chemotherapy Prior intrapleural cytotoxic agents (including bleomycin) do not count towards prior cytotoxic chemotherapy • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered • No prior radiotherapy to the only site of measurable disease • At least 4 weeks since prior radiotherapy and recovered • At least 4 weeks since prior major surgery and recovered • More than 30 days since prior participation in an investigational trial • No prior treatment with a vascular endothelial growth factor (VEGF) inhibitor • No other concurrent investigational agents • No concurrent commercial agents for the malignancy • No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, or pentamidine) • No concurrent hematopoietic growth factors except epoetin alfa • No concurrent palliative radiotherapy • No combination antiretroviral therapy for HIV-positive patients • No concurrent drugs or biologics with proarrhythmic potential

Courtesy of ClinicalTrials.gov,

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney